PHILADELPHIA (PRWEB) SEPTEMBER 10, 2020
Zelira’s first oral care product will be a proprietary toothpaste formulation, containing cannabinoids including CBD, and developed by SprinJene® CEO and Founder Dr. Sayed Ibrahim. The first product is expected to launch by the end of the year, with distribution across retail and other channels across the US. The brand will be Zelira’s first over-the-counter cannabinoid product line, and one of five new products the company is on track to launch globally this year.
SprinJene® Gluten-Free, Cruelty-Free, Vegan, Kosher, USDA Bio-preferred, and Halal oral care products are currently manufactured by Health and Natural Beauty USA Corp., a New Jersey based GMP contract manufacturing company where the Zelira-SprinJene products will be manufactured. SprinJene® products are available nationwide at retailers including Walmart, Costco, Bed Bath & Beyond, Amazon, and VitaCost.
“The SprinJene® team is excited about the partnership with Zelira Therapeutics and we look forward to the impact that our products will have in the oral care market,” says Dr. Sayed Ibrahim, CEO of SprinJene. “Our collaboration to commercialize the most advanced hemp-derived cannabinoid-based oral care products expands our reach into new oral care markets where every person can access the daily benefit of using our products.”
“Zelira is pleased to partner with Dr. Ibrahim to commercialize these new and advanced oral care cannabinoid-based products,” says Dr. Oludare Odumosu, Zelira’s CEO & Managing Director (USA). “We remain focused on unlocking the benefits of cannabinoid-based applications as we expand our company’s reach into new and lucrative markets. ”
About Zelira Therapeutics
Zelira Therapeutics Ltd is a leading global therapeutic medical cannabis company with access to the world’s largest and fastest growing cannabis markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020. The company is focused on developing branded cannabis products for the treatment of a variety of medical conditions including insomnia, autism and chronic non-cancer pain.
Zelira has two proprietary formulations under the HOPE™ brand that are generating revenues in Pennsylvania and have been licensed in Louisiana with other states in the US expected to follow. Zelira has also developed Zenivol™, a leading cannabinoid-based medicine for treatment of chronic insomnia, which has successfully completed the world's first Phase 2a clinical trial for chronic insomnia.
Zelira conducts this work in partnership with world-leading researchers and organizations including Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent’s Hospital in Melbourne, Australia; and the Children’s Hospital of Philadelphia (CHOP) in the United States.
SprinJene® is a socially conscious brand dedicated to marrying the benefits of science and nature in the creation of Gluten-Free, Cruelty-Free, Vegan, Kosher and Halal oral care products that are void of harsh chemicals and abrasives. SprinJene’s mission is to deliver the most advanced, safe, gentle and natural oral care options for brushers of all lifestyles. The company firmly believes that oral health is the gateway to internal health; that’s why every SprinJene toothpaste features its patented formula of cold pressed black seed oil and zinc. There are currently two oral care product lines under the SprinJene umbrella: SprinJene Original® and SprinJene Natural®. SprinJene continues to source the globe for advanced, healthy ingredients to include in their products in order to improve the oral wellness of brushers everywhere. The staff at SprinJene® are dedicated to continually advancing their cGMP processes, products and certifications to provide the best oral care products. https://sprinjene.com/
Article source : http://www.prweb.com/releases/zelira_partners_with_sprinjene_to_launch_cannabinoid_based_oral_care_products_in_the_u_s_hemp_derived_cbd_dental_products_to_debut_q4_2020/prweb17384117.htm